Skip to main content

Gene Therapy Deal Benchmarks in Oncology

Median Upfront
$253M
Range: $141M - $357M
Total Deal Value
$1.6B
Range: $1.0B - $2.2B
Royalty Rate
11.7% - 19.2%
Tiered up to 23.2%
Dev Milestones
$338M
Range: $226M - $452M
Model Your Deal

Market Analysis

Gene Therapy therapies in oncology have seen significant M&A and licensing activity in recent years. Based on analysis of 1,500+ verified transactions, the median upfront payment for a Phase 2 gene therapy asset in oncology is $253M, with total deal values reaching $1.6B. Development milestones average $338M, while regulatory milestones contribute $540M.

The oncology gene therapy landscape is characterized by high competitive intensity with numerous active programs and a rapidly evolving standard of care. ADCs, bispecifics, and radiopharmaceuticals continue to drive premium valuations across solid and hematologic tumors. The recommended deal structure allocates approximately 16% to upfront payments and 84% to milestones, reflecting the risk-reward profile at the Phase 2 stage.

Royalty rates for gene therapy oncology deals range from 11.7% to 19.2% at the base tier, with tiered escalation reaching 15.7%-23.2% on blockbuster sales. Commercial milestones averaging $473M further reward successful market penetration.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the typical upfront for a gene therapy oncology licensing deal?
Based on our analysis, Phase 2 gene therapy licensing deals in oncology average $253M in upfront payments, with a range of $141M to $357M depending on data quality, competitive positioning, and territorial scope.
What is the total deal value for gene therapy oncology transactions?
The median total deal value for Phase 2 gene therapy assets in oncology is $1.6B, ranging from $1.0B to $2.2B. This includes development milestones ($338M), regulatory milestones ($540M), and commercial milestones ($473M).
What royalty rates are standard for gene therapy deals in oncology?
Base royalty rates for gene therapy oncology transactions range from 11.7% to 19.2%, with tiered escalations reaching 15.7%-23.2% on peak sales. Rates are influenced by mechanism differentiation, competitive landscape, and territorial scope.
How are milestones structured in gene therapy oncology deals?
Gene Therapy oncology deals allocate approximately 84% of total deal value to milestones. Development milestones ($338M) make up the largest share, followed by commercial milestones ($473M) and regulatory milestones ($540M).
PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Related Benchmarks

Small Molecule in Oncology

View

Monoclonal Antibody in Oncology

View

Gene Therapy in Neurology

View

Gene Therapy in Metabolic & Obesity

View

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.

Start Calculating
For Funds & Advisors

Need the full deal landscape?

The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.

Configure Brief — $2,500All-inclusive · White-label · Walkthrough included